Observation of the Therapeutic Effects of Inhaled N-acetylcysteine Combined with Ustekinumab in the Treatment of Severe Pneumonia
[Objective]To investigate the curative effect of inhaled acetylcysteine combined with ulinastatin in the treatment of severe pneumonia.[Methods]A total of 110 patients with severe pneumonia admitted to our hos-pital from March 2021 to March 2023 were randomly divided into control group(receiving inhaled acetylcysteine combined with anti-infection treatment)and the observation group(receiving combined ulinastatin treatment on the basis of control group)with a ratio of 1:1(55 cases in each group).All patients were treated for 2 weeks.The clinical efficacy,the time of fever reduction,the time of lung rales and cough disappearance,and the incidence of adverse reactions were compared between the two groups.Serum inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)],blood gas analysis indicators[PaO2,SaO2 and PaCO2],acute physiology and chronic health status score System Ⅱ(APACHE Ⅱ)score were compared as well.[Results]The total effective rate of the observation group was 90.91％,which was significantly higher than 76.36％of the control group,and the difference was statistically significant(P＜0.05).The time of fever reduc-tion and disappearance of lung rales and cough in the observation group were significantly shorter than those in the control group(P＜0.05).After 2 weeks of treatment,the levels of IL-6,TNF-α,CRP and PaCO2 in observation group were lower than those in control group(P＜0.05),while PaO2 and SaO2 were significantly higher than those in control group(P＜0.05).After 2 weeks of treatment,the physiological scores and chronic health status scores of the observation group were significantly lower than those of the control group,with statistical signifi-cance(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).[Conclusion]Inhaled acetylcysteine combined with ulinastatin is effective in the treatment of patients with severe pneumonia,which can effectively improve respiratory function and reduce inflammation without in-creasing the incidence of adverse reactions.It is worthy of clinical application.
万方数据
维普
